FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study (Q33823212)

29 July 2017

title

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study (English)

1 reference

29 July 2017

1 reference

1 reference

12

Julien Taieb

1 reference

29 July 2017

1

Aziz Zaanan

1 reference

29 July 2017

Isabelle Trouilloud

2

1 reference

29 July 2017

Theofano Markoutsaki

3

1 reference

29 July 2017

Mélanie Gauthier

4

1 reference

29 July 2017

Anne-Claire Dupont-Gossart

5

1 reference

29 July 2017

Thierry Lecomte

6

1 reference

29 July 2017

Thomas Aparicio

7

1 reference

29 July 2017

Pascal Artru

8

1 reference

29 July 2017

Anne Thirot-Bidault

9

1 reference

29 July 2017

Fanny Joubert

10

1 reference

29 July 2017

Daniella Fanica

11

1 reference

29 July 2017

language of work or name

English

0 references

publication date

14 June 2014

1 reference

29 July 2017

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

page(s)

441

1 reference

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Estimates of cancer incidence and mortality in Europe in 2008.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Second-line therapy in refractory pancreatic cancer. results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4075567

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

29 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-441

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24929865

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-14-441

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference